Liu Meifang, Zhang Cai
School of Pharmaceutical Sciences, Institute of Immunopharmacology and Immunotherapy, Shandong University, Jinan, China.
Front Immunol. 2017 Jun 13;8:695. doi: 10.3389/fimmu.2017.00695. eCollection 2017.
Innate lymphoid cells (ILCs) are a recently identified group of innate immune cells lacking antigen-specific receptors that can mediate immune responses and regulate tissue homeostasis and inflammation. ILCs comprise group 1 ILCs, group 2 ILCs, and group 3 ILCs. These ILCs usually localize at mucosal surfaces and combat pathogens by the rapid release of certain cytokines. However, the uncontrolled activation of ILCs can also lead to damaging inflammation, especially in the gut, lung, and skin. Although the physiological and pathogenic roles of ILCs in liver diseases have been attracting increasing attention recently, there has been no systematic review regarding the roles of ILCs in immune-mediated liver diseases. Here, we review the relationships between the ILC subsets and their functions in immune-mediated liver diseases, and discuss their therapeutic potential based on current knowledge about the functional roles of these cells in liver diseases.
固有淋巴细胞(ILCs)是最近发现的一类固有免疫细胞,缺乏抗原特异性受体,可介导免疫反应并调节组织稳态和炎症。ILCs包括1型ILCs、2型ILCs和3型ILCs。这些ILCs通常定位于黏膜表面,通过快速释放某些细胞因子来对抗病原体。然而,ILCs的不受控制的激活也会导致破坏性炎症,尤其是在肠道、肺部和皮肤。尽管ILCs在肝脏疾病中的生理和致病作用最近越来越受到关注,但尚未有关于ILCs在免疫介导的肝脏疾病中作用的系统综述。在此,我们综述了ILC亚群与其在免疫介导的肝脏疾病中的功能之间的关系,并根据目前关于这些细胞在肝脏疾病中功能作用的知识讨论了它们的治疗潜力。